As of 2024, Brazil's Semaglutide market was estimated at $581 million. The global market size for the GLP-1 (glucagon-like ...

Experts say supplement companies have tried to capitalize on the GLP-1 craze, putting the phrase in their product names, ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

As weight-loss drug sales surge with semaglutide's patent expiration, Gujarat's Shaily Engineering Plastics, an injector pen manufacturer, anticipates significant growth. Its stock has nearly doubled, ...

Ozempic (semaglutide) and other GLP-1 medications have helped many people lose weight and manage chronic conditions like type ...

A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will need to show more robust growth in the months ahead to bolster market ...

CagriSema vs placebo was associated with significant weight loss among adults with overweight or obesity with or without type 2 diabetes.

DehydraTECH-semaglutide reduces overall side effects by 36.5% as compared to Rybelsus®DehydraTECH-semaglutide reduces gastrointestinal side effects by 43.5% as compared to Rybelsus®DehydraTECH-GLP-1 s ...

These five upcoming data drops could usher in more effective and convenient therapies for Alzheimer’s disease and open up ...

Detailed price information for Lexaria Bioscience Corp (LEXX-Q) from The Globe and Mail including charting and trades.

Several anti-obesity drugs, including Ozempic, Wegovy and Mounjaro, have created buzz in the Indian markets. But are they really approved for use in India? What are their side-effects? And how much do ...

Powerful new medications such as Ozempic and Mounjaro, known as GLP-1 drugs are helping to win the war against obesity in ...